What it actually means that the NHS hit its 150-day clinical trial target
In March 2026, the United Kingdom did something it had been failing at for over a decade. The average time to set up a commercial interventional clinical trial, measured across the system, fell to 122 days. The target was 150. The starting point, when the reform programme began, was around 250.
This is not a small operational metric. It is one of the most consequential changes the National Health Service has made to its research posture since the foundation of the National Institute for Health and Care Research itself. Behind the headline number sits a structural reorganisation of how NHS trusts contract with industry sponsors, how regulatory review is sequenced, how research is treated relative to clinical care, and how funding flows. The metric is the visible signal. The reform is the substance.
This article explains what changed, why it matters, and what the next few years will demand if the gains are to be held.
Why the United Kingdom slipped
The drift is older than most observers acknowledge. For roughly a decade up to 2023, the UK’s share of global commercial clinical trial activity declined steadily. Sponsors who had historically chosen the NHS for late-phase studies, attracted by its scale, its single-payer structure, and its high-quality data, increasingly chose elsewhere. The reasons were structural, not individual. Set-up times had crept upwards, contracting was inconsistent across trusts, regulatory and ethics review was not joined up, and the workforce capacity to support research had been eroded by clinical pressures.
The Lord O’Shaughnessy review in May 2023 set out the diagnosis with unusual clarity. It also set out a remediation plan, with commitments around contract standardisation, faster combined regulatory and ethics review, primary care integration, and the development of dedicated commercial research delivery infrastructure. The 150-day target was the headline commitment. Hitting it would signal that the UK had stopped the slide.
What the 150-day number is actually measuring
The metric tracks the time from application receipt to first patient recruited at site, across commercial interventional studies on the Research Delivery Network portfolio. It is decomposed into three sub-stages: combined Medicines and Healthcare products Regulatory Agency and Research Ethics Committee review (target: 60 days), study opening at site (target: 60 days), and first participant recruited (target: 30 days).
Hitting an aggregate of 150 days requires improvement at every stage. In practice, the gains have come predominantly from the second stage, where standardised contracting and the elimination of duplicative trust-by-trust negotiation have removed weeks from the typical timeline. Regulatory review now completes in under 60 days for the substantial majority of studies, and ethics approval is sequenced rather than serial.
The investments that produced this are not negligible. The Department of Health and Social Care has reported over £137 million spent on research infrastructure and reforms, including £45 million in research capability funding for NHS organisations and £92.5 million for the launch of 35 commercial research delivery centres across the UK. A further £47.8 million was awarded by NIHR for trial-supporting equipment in early 2026, distributed across 51 NHS trusts and 79 primary care organisations.
For context: the Department of Health and Social Care invests roughly £1.6 billion each year on health research through the NIHR. The 150-day target reform is a fraction of that envelope. The point is that comparatively modest, strategically targeted spend, applied to systemic friction rather than to new science, can produce outsized capability gains.
What the NIHR actually is
The National Institute for Health and Care Research is the body through which the Department of Health and Social Care funds applied health and care research in England. It is, by budget and by output, among the largest national clinical research funders in Europe. Its remit covers funding research, sustaining the research workforce, and operating the infrastructure that allows trials to be delivered in the NHS.
That infrastructure is unusually rich and often underdescribed. It includes 20 NIHR Biomedical Research Centres, partnerships between NHS trusts and academic institutions that conduct translational research and the early-phase work that brings new treatments toward patients. It includes Clinical Research Facilities at NHS hospitals that provide dedicated space for delivering trials. It includes 15 Applied Research Collaborations, regional partnerships focused on local health and care challenges. It includes Patient Safety Translational Research Centres and the Medtech and In Vitro Diagnostic Co-operatives that work with companies on new device development.
Operationally, the Research Delivery Network, hosted by the University of Leeds since 2024 and comprising 12 Regional Research Delivery Networks across England, is the mechanism through which trials are actually delivered. The network recruited over a million participants in the period covering the COVID-19 pandemic, including the RECOVERY trial that identified dexamethasone as a mortality-reducing intervention in COVID patients receiving respiratory support. That trial alone is estimated to have saved a million lives globally. It is the kind of result the NIHR’s infrastructure exists to enable.
Research as care, not as overhead.
The most consequential structural change accompanying the 150-day target is less visible than the metric itself. As of April 2026, research has been formally embedded in the NHS Medium Term Planning Framework. From the same date, a portion of NIHR funding is tied to delivery against national targets, meaning research centres are rewarded for measurable performance rather than allocated funding based on historical patterns.
The shift in posture is the point. For most of the NHS’s history, research has been treated as a parallel activity, valued in principle but operationally separable from the delivery of care. Trusts that delivered more research did so largely because individual clinicians and academic departments made it happen, often despite rather than because of the operational priorities of the organisation. The reframing makes research a core function. The funding architecture now reflects it.
A 2018 study published in Public Health found that NHS trusts with greater NIHR-adopted clinical trial activity were associated with reduced patient mortality. The mechanism is not entirely settled, but the finding is consistent with the hypothesis that trusts running active research programmes have higher organisational quality across the board: better governance, better data, better clinician engagement, and earlier access to interventions that work. If that hypothesis is correct, the new funding architecture is doing more than improving research delivery. It is improving care.
The Life Sciences Industry Hub
The NIHR Life Sciences Industry Hub, launched in October 2025, is the single front door for commercial sponsors running trials in England. It coordinates research infrastructure into one coherent offer, standardises engagement across trusts and primary care, and removes the previous problem of sponsors needing to negotiate with multiple bodies separately.
The reform parallels what happened in defence with UK Defence Innovation. A fragmented landscape, in which entry points were many and predictability was low, was consolidated into a single mechanism with clearer accountability. The NHS got there first. The fact that the model is now being replicated in other sectors of public-sector innovation suggests the underlying lesson is widely applicable: industry needs a single number to call.
In 2025 to 2026, the United Kingdom reported 29 global firsts and 54 European firsts for first patient enrolment in clinical trials. These metrics matter because sponsors choosing where to run studies look at them as a proxy for system capability. If the UK is the country where new trials open first, sponsors run their next trials there too. The compounding effect is significant.
Primary care as the new frontier
More than half of the £47.8 million in early 2026 trial-supporting equipment funding went to primary care organisations rather than to acute hospital trusts. This is a deliberate shift. The historical concentration of clinical research in tertiary centres is a known limitation of the UK’s research model. It restricts the patient populations who can take part, narrows the conditions that get studied, and creates geographic inequalities in research access.
The move into primary care is what the NIHR has called the “right research, right setting” initiative. Mobile research vans equipped for screening and diagnostics are being deployed in counties including Leicestershire, Nottinghamshire, Cambridgeshire, and Norfolk. Diagnostic infrastructure including FibroScan equipment, AccuVein scanners, and ultrasound is being installed in GP surgeries that previously had no capacity to support trial activity. The objective is to put research within reach of patients who are not currently captured by the academic hospital research footprint.
The implications for chronic disease research, mental health research, and prevention research are considerable. Most patients with these conditions are managed in primary care. Conducting research where the patients actually are is, in retrospect, an obvious shift. It has not, until now, been operationally possible at scale.
The recruitment problem nobody is solving fast enough
Set-up times are one constraint on UK clinical research competitiveness. Recruitment rates are another, and they have not fallen in line with set-up times. The pharmaceutical industry continues to flag low patient recruitment rates and rising study costs as drags on the sector. The 150-day target answers the question of how fast a trial can open. It does not, on its own, answer how fast it can fill.
The NIHR is investing in two adjacent programmes intended to address this. Be Part of Research is a national service that allows patients to register their interest in taking part in studies relevant to their conditions and to be matched to opportunities. Our Future Health is a longer-term population cohort study that has now recruited over a million volunteers, building a research-ready population that can be approached for individual trial opportunities.
These programmes shift the model from study-by-study recruitment to a continuous, opt-in research-engaged population. The early signs are positive. The scale required to make a system-wide difference is large, and the timeline is years rather than months. The 150-day reform is the easy part. Building a population that wants to take part in research is the harder, longer project.
The risk of losing the gains
The gains of 2025 to 2026 are real, but they are not yet structural. Three risks stand out.
The first is the workforce. NHS research delivery depends on a research-active clinical workforce that has competing demands on its time. The trusts that hit the 150-day target most reliably are those with research-engaged senior clinicians who treat trial recruitment as part of their work rather than as an extracurricular activity. Sustaining that culture requires backfill, protected time, and career incentives that the NHS workforce strategy is still working through.
The second is the funding cliff. The £137 million invested in the reform programme was time-limited. The infrastructure now exists. Sustaining it, and continuing to invest in the next layer of capability, requires recurrent funding that is harder to ringfence than one-off capital investment. The decision to tie a portion of NIHR funding to delivery from April 2026 is a partial answer. The fuller answer will depend on the multi-year settlement.
The third is regulatory pressure on the MHRA’s 14-day target for early-phase trials. The agency has committed to working towards this benchmark, which would place the UK among the fastest regulatory environments in the world. Delivering it requires sustained investment in MHRA capacity at a moment when the agency is also processing a heavier workload of innovative trial designs, real-world evidence submissions, and AI-enabled medical device approvals. The risk is not that the target is wrong. The risk is that the resourcing slips while the volume rises.
What this looks like from outside
For patients, the visible change over the next two to three years will be that more trials open close to home, more conditions are studied, and the time between a new treatment becoming available internationally and being accessible to NHS patients narrows.
For researchers, the visible change is that the conversation with industry sponsors becomes simpler. The NIHR Life Sciences Industry Hub provides a single point of engagement, the Commercial Research Delivery Centres provide a scalable delivery capability, and the contracting standardisation removes one of the most persistent points of friction.
For the life sciences sector globally, the visible change is that the United Kingdom has moved from being one of the slower research environments in Europe to being one of the faster ones, with credible aspirations to be the fastest. Whether that holds depends on execution over the next 18 months. The system has demonstrated that it can hit ambitious targets. The next test is whether it can keep doing so when the political attention has moved elsewhere.
The 150-day milestone is a milestone, not a finish line. The work it represents is the most significant repositioning of the NHS’s research function in a generation, and the early evidence is that it is producing the gains it was designed to produce. The harder, slower work of embedding research into the fabric of NHS care, building a research-engaged population, and sustaining the funding required to keep the infrastructure operating, is now the agenda for the rest of the decade.
